TECNALIA helps with the development of a platform to improve the diagnosis and treatment of Parkinson's disease

15 December 2021

The platform helps doctors in the personalised prescription of the best therapy for patients with Parkinson’s disease

In the GiMo-Pd initiative, our centre develops a state-of-the-art technological architecture for the continuous monitoring of motor symptoms in patients with Parkinson’s disease.

Nowadays, Parkinson's disease (PD) is the second most common neurodegenerative disease. One of the limitations of its treatment is the emergence of undesired effects, such as motor fluctuations, dyskinesias and other alterations. The response of patients to the treatment is not always the same, adding a vast array of responses, which presents a problem in the patient’s proper clinical evolution.

Technological solution for patients with Parkinson’s disease

The overall objective of GiMo-PD lies in creating an innovative new platform to help doctors prescribe the best personalised therapy for each patient.

Therefore, this project is researching a technological solution that enables:

  • Neuroimaging and clinical genetic data to be acquired, integrated and analysed.
  • Ubiquitous and continuous monitoring mechanisms of the motor disorders of patients with Parkinson’s disease to be offered, seeking a personalised solution.
  • Mechanisms for the regular monitoring of motor and psychocognitive symptoms to be offered.
  • An advanced analysis of all the data to be carried out so that its joint processing with clinical criteria provides specialists with support in the decision-making related to the most appropriate treatment for each patient.